Lisata Therapeutics

Breakthrough Trials And Global Trends Will Redefine Oncology

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

16 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$32.00

92.5% undervalued

21 Aug

US$2.40

-18.6%

-9.9%

Author's Valuation

US$32.0

92.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$32.0

92.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

70.53%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$2.61m

Earnings '28

148.00x

PE Ratio '28

US$387.01m

Market Cap '28

US$387.01m

Market Cap '28

9.93m

No. shares '28

US$38.95

Share Price '28

US$38.95 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$32.00

Fair Value '25